Published in:
01-08-2019 | Dabigatran | LETTER TO THE EDITOR
After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention?
Authors:
Andrea Rubboli, Matteo Lisi
Published in:
Cardiovascular Drugs and Therapy
|
Issue 4/2019
Login to get access
Excerpt
In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention with stent (PCI), prospective, randomized evidence on the combination of a direct oral anticoagulant (DOAC) with the single antiplatelet agent clopidogrel (so-called double therapy) is [
1‐
3], or soon will be [
4], available for all four agents dabigatran, rivaroxaban, apixaban, and edoxaban [
4]. Apixaban is currently the only DOAC being tested in combination with dual antiplatelet therapy (DAPT) of aspirin and clopidogrel (so-called triple therapy) in AF patients undergoing PCI [
3]. Should therefore apixaban be the only DOAC to be used in triple therapy whenever this regimen is selected, and even when at the time of PCI the patient was in chronic oral anticoagulation (OAC) with another DOAC? …